ArticleCancer research communications2026

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

Jong Chul Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.